5500 Reported lives saved with the help of EVZIO based on voluntary reports from recipients of donated product
5500 Reported lives saved with the help of EVZIO based on voluntary reports from recipients of donated product
EVZIO—an auto-injector designed to be easy to use—provides simple, on-the-spot voice and visual guidance to help those with no medical training administer naloxone during an opioid overdose. EVZIO is not a substitute for emergency medical care.
Seek emergency medical assistance immediately after use. The use of EVZIO may result in symptoms of acute opioid withdrawal.
*Sample story.
Government agencies, first responders, health departments, and other qualifying groups can get EVZIO at public access pricing.
EVZIO—an auto-injector designed to be easy to use. EVZIO is not a substitute for emergency medical care.
To report an adverse event or product complaint about EVZIO, please call 1-855-625-6966.
EVZIO is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adults and pediatric patients. EVZIO is intended for immediate administration as emergency therapy in settings where opioids may be present. EVZIO is not a substitute for emergency medical care.
EVZIO is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the ingredients in EVZIO.
Seek emergency medical assistance immediately after use. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance.
The following warnings and precautions should be taken when administering EVZIO:
The following adverse reactions were most commonly observed in EVZIO clinical studies: dizziness and injection site erythema.
Abrupt reversal of opioid effects in persons who were physically dependent on opioids has precipitated signs and symptoms of opioid withdrawal including: body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and tachycardia. In the neonate, opioid withdrawal signs and symptoms also included: convulsions, excessive crying, and hyperactive reflexes.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please click for full Prescribing Information and Patient Information.
EVZIO is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adults and pediatric patients. EVZIO is intended for immediate administration as emergency therapy in settings where opioids may be present. EVZIO is not a substitute for emergency medical care.
EVZIO is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the ingredients in EVZIO.
EVZIO is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adults and pediatric patients. EVZIO is intended for immediate administration as emergency therapy in settings where opioids may be present. EVZIO is not a substitute for emergency medical care.
EVZIO is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the ingredients in EVZIO.
EVZIO is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adults and pediatric patients. EVZIO is intended for immediate administration as emergency therapy in settings where opioids may be present. EVZIO is not a substitute for emergency medical care.
EVZIO is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the ingredients in EVZIO.